Immunotherapy delays type 1 diabetes diagnosis in people at high risk
Published 10 June 2019 Presented on June 9 at the 2019 American Diabetes Association’s 79th Scientific Sessions and published in the New England Journal of Medicine (nejm.org), findings from TrialNet’s Teplizumab (anti-CD3) Prevention Study show a drug that targets the immune system can delay type 1 diabetes a median of 2 years in children and adults at high risk. “This is great news for millions
https://www.ludc.lu.se/article/immunotherapy-delays-type-1-diabetes-diagnosis-people-high-risk - 2025-07-13